within Pharmacolibrary.Drugs.ATC.R;

model R06AX26
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.33,
    Cl             = 9.5e-05,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.135,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01933333333333333,
    Tlag           = 10.020000000000001,            
    Vdp             = 0.104,
    k12             = 13.1,
    k21             = 13.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R06AX26</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fexofenadine is a second-generation antihistamine used to treat allergy symptoms such as hay fever (allergic rhinitis) and urticaria (hives). It is a non-sedating antihistamine and is widely approved for clinical use globally for symptomatic relief of allergic conditions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers following a single oral dose.</p><h4>References</h4><ol><li><p>Ansotegui, IJ, et al., &amp; Scadding, GK (2024). Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review. <i>Current medical research and opinion</i> 40(8) 1297–1309. DOI:<a href=&quot;https://doi.org/10.1080/03007995.2024.2378172&quot;>10.1080/03007995.2024.2378172</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39028636/&quot;>https://pubmed.ncbi.nlm.nih.gov/39028636</a></p></li><li><p>Markham, A, &amp; Wagstaff, AJ (1998). Fexofenadine. <i>Drugs</i> 55(2) 269–276. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199855020-00012&quot;>10.2165/00003495-199855020-00012</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9506246/&quot;>https://pubmed.ncbi.nlm.nih.gov/9506246</a></p></li><li><p>Lappin, G, et al., &amp; Garner, C (2010). Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 40(2) 125–131. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2010.03.009&quot;>10.1016/j.ejps.2010.03.009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20307657/&quot;>https://pubmed.ncbi.nlm.nih.gov/20307657</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R06AX26;
